Omeros Corporation (OMER) Bucks Biotech Sell-Off

Omeros Corporation (NASDAQ:OMER) will begin a late-stage study of its atypical hemolytic uremic syndrome treatment

by Karee Venema

Published on Mar 8, 2016 at 12:22 PM

Despite a broader sell-off of biotechnology stocks -- per a 2.2% decline in the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) -- drugmaker Omeros Corporation (NASDAQ:OMER) is soaring on news the company will kick off a Phase 3 study for OMS721 -- its drug used to treat atypical hemolytic uremic syndrome. Additionally, OMER reported a slimmer-than-expected fourth-quarter loss. Against this backdrop, the stock is up 18.6% at $15.40 -- on track for its biggest one-day percentage gain in six months -- and call volume has jumped to seven times the average intraday rate.

While OMER option volume is relatively light on an absolute basis -- just over 1,300 total contracts have traded so far today -- calls are outpacing puts by a 17-to-1 margin. This is just more of the same, as evidenced by the stock's top-heavy 20-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 7.21.

Outside of the options arena, however, sentiment among traders is skewed toward the skeptical side. Specifically, short interest accounts for nearly 27% of OMER's available float, or 39.3 times the average daily trading volume. As such, it's possible some of today's bull gap is a result of shorts covering. Plus, a portion of the recent call buying -- particularly at out-of-the-money strikes -- could be a result of shorts hedging their bearish bets.

On the charts, Omeros Corporation (NASDAQ:OMER) has been a long-term laggard, losing 49% since hitting a record high of $30.23 in mid-August. What's more, today's rally is stalling out near the $16 mark -- a level that served as resistance in late 2015.


Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical  levels, and top economic stories straight to your inbox.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.
First Week in April Provides More Coronavirus-Related Volatility
A slew of coronavirus-related news sent markets on another weekly roller coaster ride
Netflix Stock Heading into Historically Bullish Quarter
NFLX's 10-day moving average has stepped up as support lately
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.